Panel discussions about knowledge needed by emerging company executives and changes in patent rules headline the program for the ninth annual Southeastern BIO Investor Forum.
The conference, put on by the trade group Southeast BIO, is set for November 7-8 at the Pinehurst Resort in Pinehurst, N.C.
A discussion focused on “What Emerging Companies Want to Know,” is scheduled to include:
• Rick Anderson, company group chairman, Johnson & Johnson and worldwide franchise chairman, Cordis Corporation
• Leslie Boyd, vice president of scientific licensing, GlaxoSmithKline
• Edward Mathers, executive vice president, corporate development and venture, MedImmune
Kenneth Lee, a general partner with Hatteras Venture Partners, will be the moderator.
The patent rule change panel will include:
• Margaret Bolce Brivanlou, partner, King and Spalding LLP
• Jamie Greene, partner, Kilpatrick Stockton LLP
• Todd Sherer, associate vice president of research and director Office of Technology Transfer, Emory University
• Doug Gooding, chief executive officer, Regado Biosciences, Inc.
Allen Baum, a partner at Hutchison law Group, will be the moderator.
Also planned are discussions about maximizing value of assets and medical device commercialization.
The conference keynote speaker is Matthew Emmens, CEO at Shire Pharmaceuticals Group. He is scheduled to discuss challenges for global pharmaceutical companies.
“We are extremely fortunate to have such experienced executives share their knowledge with us,” said SEBIO Conference Co-Chair Fred Hutchison in a statement. “This year’s SEBIO Investor Forum presents a unique opportunity to hear first-hand from true leaders in the life sciences field and gain valuable insight into important industry trends and issues.”
The conference also will include presentations from 24 companies seeking investors.
